Discovery of novel α7 nicotinic acetylcholine receptor ligands via pharmacophoric and docking studies of benzylidene anabaseine analogs

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 2, 2012, Pages 1179-1186

  Kombo, David C ^a   Mazurov, Anatoly A ^a   Chewning, Joseph ^a   Hammond, Philip S ^a   Tallapragada, Kartik ^a   Hauser, Terry A ^a   Speake, Jason ^a   Yohannes, Daniel ^a   Caldwell, William S ^a  

^a TARGACEPT INC   (United States)

Author keywords

AChBPs; Benzylidene anabaseine analogs; Docking; Nicotinic acetylcholine receptor 7; Pharmacophore; Spirodiazepine and spiroimidazoline quinuclidine series

Indexed keywords

2 (3 AMINOBENZOFURAN 2 YL)SPIRO[1,5 DIHYDROIMIDAZOLE 4,3' QUINUCLIDINE]; 2 (3 HYDROXYBENZOFURAN 2 YL)SPIRO[1,5 DIHYDROIMIDAZOLE 4,3' QUINUCLIDINE]; 2 PHENYLSPIRO[1,5 DIHYDROIMIDAZOLE 4,3' QUINUCLIDINE]; 2 SPIRO[1,5 DIHYDROIMIDAZOLE 4,3' QUINUCLIDINE] 2 YLPHENOL; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (4 HYDROXY 2 METHOXYBENZYLIDENE)ANABASEINE; 3 AMINO 3 (AMINOMETHYL)QUINUCLIDINE; 5 PHENYLSPIRO[1,3 DIHYDRO 1,4 DIAZEPINE 2,3' QUINUCLIDINE] 7 OL; 6 PHENYLSPIRO[1,3 DIHYDRO 1,4 DIAZEPINE 2,3' QUINUCLIDINE]; 6 PHENYLSPIRO[1,4 DIAZEPANE 2,3' QUINUCLIDINE] 5,7DIONE; ACETYLCHOLINE BINDING PROTEIN; BENZYLIDENE ANABASEINE DERIVATIVE; BENZYLIDENE DERIVATIVE; BINDING PROTEIN; BUNGAROTOXIN RECEPTOR; QUINUCLIDINE DERIVATIVE; SPIRODIAZEPINE DERIVATIVE; SPIROIMIDAZOLINE QUINUCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANABASINE; BENZYLIDENE COMPOUNDS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855677154     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.090     Document Type: Article

References (31)

1. P.M. Lippiello, M. Bencherif, T.A. Hauser, K.G. Jordan, S.R. Letchworth, and A.A. Mazurov Expert Opin. Drug Discov. 2 2007 1185
2. R.J. Law, R.H. Henchman, and A. McCammon Proc. Natl. Acad. Sci. U.S.A. 102 2005 6813
3. M.J. Marks, and A.C. Collins Mol. Pharmacol. 3 1982 554
4. R. Freedman, M. Hall, L.E. Adler, and S. Leonard Biol. Psychiatry 38 1995 22
5. D. Bertrand, and M. Gopalakrishnan Biochem. Pharmacol. 74 2007 1155
6. R. Freedman, H. Coon, M. Myles-Worsley, A. Orr-Urtreger, A. Olincy, A. Davis, M. Polymeropoulos, J. Holil, J. Hopkins, M. Hoff, J. Rosenthal, M.C. Waldo, F. Reimherr, P. Wender, J. Yaw, D.A. Young, C.R. Breese, C. Adams, D. Patterson, L.E. Adler, L. Kruglyak, S. Leonard, and W. Byerley Proc. Natl. Acad. Sci. U.S.A. 94 1997 587
7. K. Brejc, W.J. van Dijk, R.V. Klaassen, M. Schhurmans, J. van de Oost, A.B. Smit, and T.K. Sixma Nature 411 2001 269
8. N. Unwin J. Mol. Biol. 346 2005 967
9. Y. Bourne, T.T. Talley, S.B. Hansen, P. Taylor, and P. Marchot EMBO J. 24 2005 1512
10. P.H. Celie, S.E. Rossum-Fikkert, W.J. van Dijk, K. Brejc, A.B. Smit, and T.K. Sixma Neuron 41 2004 907
11. P.H. Celie, R.V. Klaassen, S.E. Rossum-Fikkert, R. van Elk, P. van Nierop, A.B. Smit, and T.K. Sixma J. Biol. Chem. 280 2005 26457
12. R.E. Hibbs, G. Sulzenbacher, J. Shi, T.T. Talley, S. Conrod, W.R. Kem, P. Taylor, P. Marchot, and Y. Bourne EMBO J. 28 2009 3040
13. S. Mecozzi, A.P. West, and D.A. Dougherty Proc. Natl. Acad. Sci. U.S.A. 93 1996 10566
14. J.D. Schmitt, C.G. Sharples, and W.S. Caldwell J. Med. Chem. 42 1999 3066
15. D.A. Dougherty J. Org. Chem. 16 2008 3667
16. C. Ulens, A. Akdemir, A. Jongejan, R. van Elk, S. Bertrand, A. Perrakis, R. Leurs, A.B. Smit, T.K. Sixma, D. Bertrand, and I.J.P. de Esch J. Med. Chem. 52 2009 2372
17. R.L. Papke, E.M. Meyer, S. Lavieri, S.R. Bollompally, T.A. Papke, N.A. Horenstein, Y. Itoh, and J.K. Papke Neuropharmacology 46 2004 1023
18. C. Stokes, J.K. Papke, N.A. Horenstein, W.R. Kem, T.J. McCormack, and R.L. Papke Mol. Pharmacol. 66 2004 14
19. Docking studies were carried out using Glide 5.5 (Schrodinger, Inc., 101 SW Main Street, Suite 1300, Portland, OR 97204), as described in; Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739
20. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. J. Med. Chem. 2004, 47, 1750
21. To validate the procedure, a self-docking of 1b and its metabolite 1a into their cognate Aplysia AChBP with the structure, obtained from Hibbs, R. E.; Sulzenbacher, G.; Shi, J.; Talley, T. T.; Conrod, S.; Kem, W. R.; Taylor, P.; Marchot, P.; Bourne, Y. EMBO J. 2009, 28, 3040, was carried
22. Glide-derived docked poses were within an average rmsd of 1.3 with respect to the native co-crystalized conformation. Homology models of the extracellular domain of rat α7 nAChR were obtained using MODELLER (Accelrys Inc., San Diego, CA, 2006), as described in Eswar, N.; Marti-Renom, M. A.; Webb, B.; Madhusudhan, M. S.; Eramian, D.; Shen, M.; Pieper, U.; Sali, A. Comparative Protein Structure Modeling With MODELLER, In Current Protocols in Bioinformatics, John Wiley & Sons; 2006, Supplement 15, 5.6.1-5.6.30, 200
23. Marti-Renom, M. A.; Stuart, A.; Fiser, A.; Sánchez, R.; Melo, F.; Sali, A. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291.
24. The crystal structure of AChBP from lymnaea complexed with nicotine (pdb code 1uw6) was used as template. The derived protein models were validated using Procheck (Laskowski, R. A.; MacArthur, M. W.; Moss, D. S; Thornton, J. M. App. Cryst. 1993, 26, 283) and Verify3D
25. i > 500 nM). Glide performance to rank these compounds with respect to their binding affinity, was evaluated by means of the area under the receiver operating characteristic (ROC) curve. The accuracy obtained was 0.74.
26. G. Mullen, J. Napier, M. Balestra, T. DeCory, G. Hale, J. Macor, R. Mack, J. Loch, E. Wu, A. Kover, P. Verhoest, A. Sampognaro, E. Phillips, Y. Zhu, R. Murray, R. Griffith, J. Blosser, D. Gurley, A. Machulskis, J. Zongrone, A. Rosen, and J. Gordon J. Med. Chem. 43 2000 4045
27. Binding assays to membrane bound nicotinic receptors were carried out using standard methods adapted from published procedures, for example, Lippiello, P. M.; Fernandes, K. G. Mol. Pharmacol. 1986, 29, 448
28. Davies, A. R.; Hardick, D. J.; Blagbrough, I. S.; Potter, B. V.; Wolstenholme, A. J.; Wonnacott, S. Neuropharmacology 1999, 38, 679.
29. i values were calculated using the Cheng-Prusoff equation, Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099.
30. B.A. Puodzhyunaite, R.A. Yanchene, and P.B. Terent'ev Chem. Heterocycl. Compd. 16 1988 311
31. S.A. Andronati, V.S. Yur'eva, A.A. Mazurov, and L.E. Nivorozhkin Chem. Heterocycl. Compd. 20 1984 451